| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1385-299X(96)00037-2 |
| P698 | PubMed publication ID | 9385062 |
| P50 | author | Cesar V. Borlongan | Q39649000 |
| P2093 | author name string | Hauser RA | |
| Sanberg PR | |||
| Freeman TB | |||
| Cahill DW | |||
| Koutouzis TK | |||
| P2860 | cites work | Effects of intrastriatal injections of the cholinergic neurotoxin AF64A on spontaneous nocturnal locomotor behavior in the rat | Q48669287 |
| Nocturnal paroxysmal dystonia | Q33622114 | ||
| Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract | Q39843819 | ||
| Learning impairments following selective kainic acid-induced lesions within the neostriatum of rats | Q41635507 | ||
| Relationship of some open-field behaviors to amygdaloid kindled convulsions in Wistar rats | Q44951770 | ||
| The quinolinic acid model of Huntington's disease: locomotor abnormalities | Q45021251 | ||
| Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease | Q45291692 | ||
| Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats | Q45307246 | ||
| Systemic 3-nitropropionic acid: long-term effects on locomotor behavior | Q48121479 | ||
| P433 | issue | 3 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 253-257 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Brain Research Protocols | Q16039923 |
| P1476 | title | Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model | |
| P478 | volume | 1 |
| Q37718532 | 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future. |
| Q45299994 | 3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease |
| Q33992451 | 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme |
| Q42517324 | Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. |
| Q35055022 | Altered Balance of Activity in the Striatal Direct and Indirect Pathways in Mouse Models of Huntington's Disease |
| Q34665829 | Animal models of Huntington's disease |
| Q46863278 | Behavioral alterations in Lewis rats following two-day continuous 3-nitropropionic acid administration |
| Q43694197 | Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation |
| Q48315550 | Chronic cyclosporine-A injection in rats with damaged blood-brain barrier does not impair retention of passive avoidance |
| Q42436464 | Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats |
| Q45301207 | Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease |
| Q44722641 | Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study |
| Q45301294 | Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene |
| Q35184309 | Glycogen accumulation in cardiomyocytes and cardiotoxic effects after 3NPA treatment |
| Q36306882 | Heterogeneous nuclear ribonucleoprotein A1 post-transcriptionally regulates Drp1 expression in neuroblastoma cells |
| Q42472433 | Huntington's disease and mitochondrial alterations: emphasis on experimental models |
| Q37494307 | Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. |
| Q73304376 | Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease |
| Q42932168 | N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity |
| Q64236281 | Peroxisomal Malfunction Caused by Mitochondrial Toxin 3-NP: Protective Role of Oxytocin |
| Q45305500 | Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity |
| Q28533959 | Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats |
| Q38055455 | Stem cell-based therapy for Huntington's disease |
| Q60912328 | Striatal Neurodegeneration that Mimics Huntington's Disease Modifies GABA-induced Currents |
| Q37741509 | Tert-buthylhydroquinone pre-conditioning exerts dual effects in old female rats exposed to 3-nitropropionic acid |
| Q52149719 | The N-Methyl-d-Aspartate Receptor Antagonist MK-801 Prevents Thallium-Induced Behavioral and Biochemical Alterations in the Rat Brain |
| Q42694001 | Zdhhc13-dependent Drp1 S-palmitoylation impacts brain bioenergetics, anxiety, coordination and motor skills |
Search more.